Relapsed or Refractory B Cell Malignancies Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Type (Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, and Others), By Disease Type (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Acute Lymphoblastic Leukaemia, and Chronic Lymphocytic Leukaemia), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Region Forecast 2020-2031

Relapsed or Refractory B Cell Malignancies Market is expected to have a considerable share during the forecast period. The Global Relapsed or Refractory B Cell Malignancies Market focuses on the development, production, and commercialization of therapies for B cell cancers such as diffuse large B-cell lymphoma (DLBCL) and other non-Hodgkin lymphomas that have either relapsed or are refractory.

The Global Relapsed or Refractory (R/R) B-Cell Malignancies Market is being primarily driven by the rapid advancement and clinical success of CAR-T cell therapies, which have revolutionized treatment paradigms by delivering durable remissions in patients resistant to standard therapies. Approvals of products like Yescarta and Kymriah, along with continued innovation in allogeneic and combination strategies, are propelling growth. A prominent trend in the market is the rising adoption of bispecific antibodies, such as glofitamab and epcoritamab, offering off-the-shelf convenience, strong efficacy, and easier administration compared to CAR-T, particularly in outpatient settings.

A key opportunity lies in the ongoing development of allogeneic cell therapies, which promise to reduce treatment delays and costs by using donor cells, thus improving scalability and access globally. Simultaneously, AI-driven clinical trial optimization and expanding investment in emerging markets are enhancing future commercial potential. However, the market faces significant restraints, notably the high cost, complex logistics, and infrastructure demands of current CAR-T therapies, which limit accessibility in both developed and resource-constrained settings. Reimbursement hurdles and post-treatment relapses also temper broader

Facts & Figures

• Rise of Bispecific Antibodies: Off-the-shelf, immune-engaging bispecifics offer potent responses with easier administration compared to CAR-T. For instance, in April 2025, Regeneron’s linvoseltamab (BCMA×CD3) was approved in the EU for relapsed/refractory multiple myeloma, reflecting the increasing regulatory momentum behind bispecifics.
• Expansion of Allogeneic and Off-the-Shelf Platforms: Allogeneic CAR-T therapies reduce production timelines, enabling scalable and accessible solutions. For instance, in Q1 2025, Cellectis and AstraZeneca advanced multiple allogeneic CAR-T programs (UCART20x22 for B-NHL), emphasizing pharma’s shift toward scalable immunotherapy platforms.
• Breakthroughs in CAR-T Cell Therapy: AR-T therapies continue to dominate the treatment paradigm for R/R B-cell malignancies due to their curative potential in patients with limited options. For instance, in March 2025, Bristol Myers Squibb acquired 2seventy bio for $286M, consolidating full rights over Abecma, its BCMA-targeted CAR-T, signalling continued confidence in the cell therapy space.
• Regulatory Streamlining and Approvals: Faster regulatory approvals and reduced administrative burdens are boosting therapy availability. For instance, on June 27, 2025, the FDA removed the REMS (Risk Evaluation and Mitigation Strategy) requirements for all CAR-T therapies, improving operational ease for hospitals and expanding adoption.

Key Developments

• In March 2025, Bristol?Myers Squibb acquired 2seventy bio in $286?M deal, its Abecma co?developer, to streamline commercialization and own full profit from its BCMA?directed CAR?T therapy.
• In January 2025, Cellectis is advancing two allogeneic CAR?T programs (UCART22 for B?ALL and UCART20x22 for R/R B?NHL) under its multi-program strategic alliance with AstraZeneca.
• In October 2024, Merck finalized a $700?million upfront deal (up to $1.3?billion total) to add CN201, a CD3×CD19 bispecific antibody, in Phase I/Ib/II trials for R/R NHL and B-ALL, demonstrating strong B-cell depletion potential
• In July 2023, AstraZeneca acquired TeneoTwo, gaining control of TNB-486, a next-generation CD19×CD3 bispecific designed for lower cytokine release, reinforcing its hematologic oncology pipeline.

Relapsed or Refractory B Cell Malignancies Market Segmentation

Based on the drug type

• Monjuvi
• XPOVIO
• Polivy
• Kymriah
• Yescarta
• Others

Based on drug type, Yescarta (axicabtagene ciloleucel) currently holds the largest market share in the Global Relapsed or Refractory B-cell malignancies Market. As a leading CAR-T cell therapy approved for multiple B-cell malignancies, including DLBCL and PMBCL, Yescarta has demonstrated superior response rates and durable remissions, driving strong physician adoption globally. Its wide label coverage, early FDA approval, and expanded access following the recent removal of REMS restrictions by the FDA in 2025 have further strengthened its market position. On the other hand, XPOVIO, a selective nuclear export inhibitor, holds the smallest market share due to limited efficacy in aggressive R/R B-cell lymphomas and narrower clinical utility.

Based on the disease type

• Diffuse Large B-Cell Lymphoma (DLBCL)
• Follicular Lymphoma (FL)
• Mantle Cell Lymphoma (MCL)
• Acute Lymphoblastic Leukaemia (ALL)
• Chronic Lymphocytic Leukaemia (CLL)

Based on disease type, Diffuse Large B-Cell Lymphoma (DLBCL) holds the largest market share in the Global Relapsed or Refractory B-Cell Malignancies Market. DLBCL is the most common and aggressive subtype, accounting for nearly 30–40% of all non-Hodgkin lymphoma cases globally. Its high relapse rate and poor prognosis in refractory settings have driven significant clinical focus, leading to the approval of advanced therapies like Yescarta, Polivy, and bispecific antibodies such as glofitamab. These targeted innovations have expanded treatment options and boosted market value. In contrast, Mantle Cell Lymphoma (MCL) represents the smallest share, due to its lower prevalence and more limited therapeutic pipeline.

Based on the distribution channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Based on the distribution channel, hospital pharmacy holds the largest market share in the Global Relapsed or Refractory B-Cell Malignancies Market. This dominance is driven by the nature of advanced therapies like CAR-T cells (e.g., Yescarta, Kymriah) and bispecific antibodies, which require controlled administration, patient monitoring, and specialized infrastructure, only available in hospital settings. Hospitals also handle most infusion-based therapies and serve as key centers for oncology treatment under strict protocols. While Retail Pharmacy plays a role in dispensing oral agents like XPOVIO, and Online Pharmacy is growing in chronic care, their presence in this market remains limited due to clinical complexity.